Corcept Therapeutics (CORT) Income from Continuing Operations (2010 - 2026)

Corcept Therapeutics has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 31761000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 31761000.0, down 254.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 47344000.0 (down 64.67% YoY), and the FY2025 annual result was 99652000.0, down 29.43% from the prior year.
• Income from Continuing Operations came in at 31761000.0 for Q1 2026 at Corcept Therapeutics, down from 24288000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 47243000.0 in Q3 2024 to a low of 31761000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 27530000.0 (2023), against an average of 24505647.06.
• Across the five-year window, Income from Continuing Operations jumped 89.07% in 2023 and sank 254.8% in 2026, its largest moves.
• Corcept Therapeutics' Income from Continuing Operations stood at 16603000.0 in 2022, then soared by 89.07% to 31392000.0 in 2023, then retreated by 2.06% to 30746000.0 in 2024, then fell by 21.0% to 24288000.0 in 2025, then plunged by 230.77% to 31761000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 31761000.0 (Q1 2026), 24288000.0 (Q4 2025), and 19668000.0 (Q3 2025), per Business Quant data.